Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240057463
Category : Medical
Languages : en
Pages : 77
Book Description
Preferred product characteristics” (PPCs) are key tools to incentivize and guide the development of urgently needed health products. The PPCs published here aim to articulate the public health need, preferred characteristics, and clinical development considerations for new malaria vaccines. WHO PPCs were initially conceived in 2012-2013 as a class of research-oriented normative guidance documents. The first edition of the WHO PPCs for malaria vaccines (WHO/IVB/14.09), published in 2014, was the first-in-class of these documents. The document published here is an update to the 2014 edition. Since the first malaria vaccine PPCs were published in 2014, major milestones in malaria vaccine R&D have been achieved. In 2021, RTS,S/AS01 became the first malaria vaccine to be recommended by WHO for use in moderate- to high-transmission settings in sub-Saharan Africa. However, a healthy market of vaccines will be needed to meet the global demand. A continued focus on developing new and improved vaccines will be vital in our efforts to reduce global malaria burden and to achieve elimination and eradication. This includes malaria vaccines to prevent blood-stage infection, reduce morbidity and mortality, and/or reduce community-level transmission.
Malaria vaccines: preferred product characteristics and clinical development considerations
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240057463
Category : Medical
Languages : en
Pages : 77
Book Description
Preferred product characteristics” (PPCs) are key tools to incentivize and guide the development of urgently needed health products. The PPCs published here aim to articulate the public health need, preferred characteristics, and clinical development considerations for new malaria vaccines. WHO PPCs were initially conceived in 2012-2013 as a class of research-oriented normative guidance documents. The first edition of the WHO PPCs for malaria vaccines (WHO/IVB/14.09), published in 2014, was the first-in-class of these documents. The document published here is an update to the 2014 edition. Since the first malaria vaccine PPCs were published in 2014, major milestones in malaria vaccine R&D have been achieved. In 2021, RTS,S/AS01 became the first malaria vaccine to be recommended by WHO for use in moderate- to high-transmission settings in sub-Saharan Africa. However, a healthy market of vaccines will be needed to meet the global demand. A continued focus on developing new and improved vaccines will be vital in our efforts to reduce global malaria burden and to achieve elimination and eradication. This includes malaria vaccines to prevent blood-stage infection, reduce morbidity and mortality, and/or reduce community-level transmission.
Publisher: World Health Organization
ISBN: 9240057463
Category : Medical
Languages : en
Pages : 77
Book Description
Preferred product characteristics” (PPCs) are key tools to incentivize and guide the development of urgently needed health products. The PPCs published here aim to articulate the public health need, preferred characteristics, and clinical development considerations for new malaria vaccines. WHO PPCs were initially conceived in 2012-2013 as a class of research-oriented normative guidance documents. The first edition of the WHO PPCs for malaria vaccines (WHO/IVB/14.09), published in 2014, was the first-in-class of these documents. The document published here is an update to the 2014 edition. Since the first malaria vaccine PPCs were published in 2014, major milestones in malaria vaccine R&D have been achieved. In 2021, RTS,S/AS01 became the first malaria vaccine to be recommended by WHO for use in moderate- to high-transmission settings in sub-Saharan Africa. However, a healthy market of vaccines will be needed to meet the global demand. A continued focus on developing new and improved vaccines will be vital in our efforts to reduce global malaria burden and to achieve elimination and eradication. This includes malaria vaccines to prevent blood-stage infection, reduce morbidity and mortality, and/or reduce community-level transmission.
Monoclonal antibodies for malaria prevention: preferred product characteristics and clinical development considerations
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240070982
Category : Medical
Languages : en
Pages : 36
Book Description
Preferred product characteristics (PPCs) are key tools to incentivize and guide the development of urgently needed health products. The PPCs published here aim to articulate the public health need, preferred characteristics, and clinical development considerations for monoclonal antibodies (mAbs) for malaria prevention. Alongside the development of new malaria vaccines and chemoprevention drugs, there have been recent R&D advances in the development of mAbs for malaria prevention. Passive immunization with mAbs through direct administration of functional antibodies could potentially overcome some of the limitations of vaccines by providing immediate protection. Furthermore, mAbs with simplified dose regimens could potentially circumvent some of the coverage and adherence issues faced by malaria chemoprevention. To support this quickly developing R&D area, WHO convened a scientific development group to consider the PPCs for mAbs to be used for malaria prevention, with a focus on the reduction of morbidity and mortality in infants and children due to Plasmodium falciparum.
Publisher: World Health Organization
ISBN: 9240070982
Category : Medical
Languages : en
Pages : 36
Book Description
Preferred product characteristics (PPCs) are key tools to incentivize and guide the development of urgently needed health products. The PPCs published here aim to articulate the public health need, preferred characteristics, and clinical development considerations for monoclonal antibodies (mAbs) for malaria prevention. Alongside the development of new malaria vaccines and chemoprevention drugs, there have been recent R&D advances in the development of mAbs for malaria prevention. Passive immunization with mAbs through direct administration of functional antibodies could potentially overcome some of the limitations of vaccines by providing immediate protection. Furthermore, mAbs with simplified dose regimens could potentially circumvent some of the coverage and adherence issues faced by malaria chemoprevention. To support this quickly developing R&D area, WHO convened a scientific development group to consider the PPCs for mAbs to be used for malaria prevention, with a focus on the reduction of morbidity and mortality in infants and children due to Plasmodium falciparum.
World malaria report 2022
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240064893
Category : Medical
Languages : en
Pages : 372
Book Description
Each year, WHO’s World malaria report offers in-depth information on the latest trends in malaria control and elimination at global, regional and country levels. The report highlights progress towards global targets and describes opportunities and challenges for curbing and eliminating the disease. This year’s report includes three new sections on: (1) global and regional initiatives launched in 2021 and 2022; (2) global malaria surveillance and country-level case studies on surveillance systems assessments; and (3) research and development. The report also includes an expanded section on threats to malaria control, with a focus on the declining effectiveness of insecticide-treated mosquito nets.
Publisher: World Health Organization
ISBN: 9240064893
Category : Medical
Languages : en
Pages : 372
Book Description
Each year, WHO’s World malaria report offers in-depth information on the latest trends in malaria control and elimination at global, regional and country levels. The report highlights progress towards global targets and describes opportunities and challenges for curbing and eliminating the disease. This year’s report includes three new sections on: (1) global and regional initiatives launched in 2021 and 2022; (2) global malaria surveillance and country-level case studies on surveillance systems assessments; and (3) research and development. The report also includes an expanded section on threats to malaria control, with a focus on the declining effectiveness of insecticide-treated mosquito nets.
Health technologies gaps and strengthening research and development systems
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240100997
Category : Medical
Languages : en
Pages : 53
Book Description
While promising technological advances are under way to develop new health products for the fight against several poverty-related diseases, considerable gaps exist in most disease areas. During the 2023 WHO-PDP forum, PDPs, their funders and WHO deliberated on how to best close the gap for missing health technologies as well as how to build sustainable R&D systems in low- and middle income countries. Furthermore, WHO presented new initiatives and processes related to the work of PDPs and gathered feedback on the potential future role of WHO’s Science Division in the PDPs space.
Publisher: World Health Organization
ISBN: 9240100997
Category : Medical
Languages : en
Pages : 53
Book Description
While promising technological advances are under way to develop new health products for the fight against several poverty-related diseases, considerable gaps exist in most disease areas. During the 2023 WHO-PDP forum, PDPs, their funders and WHO deliberated on how to best close the gap for missing health technologies as well as how to build sustainable R&D systems in low- and middle income countries. Furthermore, WHO presented new initiatives and processes related to the work of PDPs and gathered feedback on the potential future role of WHO’s Science Division in the PDPs space.
Evidence generation for development of health products
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240084290
Category : Medical
Languages : en
Pages : 40
Book Description
This document describes the main elements that World Health Organization (WHO) technical departments should elaborate on when providing guidance on evidence generation to research and development (R&D) specialists who are developing health products to address critical unmet needs in public health. While WHO’s TPPs, preferred product characteristics (PPCs) and target regimen profiles (TRPs) provide high-level information on the desired characteristics of the product, the target population, and the key endpoints for safety and efficacy evaluation, more detailed guidance is needed to enable the development of suitable trial/study designs aimed at producing relevant evidence for WHO’s normative products such as guidelines. The objective of the Guidance for evidence generation (GEG) process is to produce a guidance document on how best to perform studies for the development of novel products (diagnostics, drugs, vaccines, vector control) and thus how to enable the generation of robust data and evidence to inform a WHO evidence review process.
Publisher: World Health Organization
ISBN: 9240084290
Category : Medical
Languages : en
Pages : 40
Book Description
This document describes the main elements that World Health Organization (WHO) technical departments should elaborate on when providing guidance on evidence generation to research and development (R&D) specialists who are developing health products to address critical unmet needs in public health. While WHO’s TPPs, preferred product characteristics (PPCs) and target regimen profiles (TRPs) provide high-level information on the desired characteristics of the product, the target population, and the key endpoints for safety and efficacy evaluation, more detailed guidance is needed to enable the development of suitable trial/study designs aimed at producing relevant evidence for WHO’s normative products such as guidelines. The objective of the Guidance for evidence generation (GEG) process is to produce a guidance document on how best to perform studies for the development of novel products (diagnostics, drugs, vaccines, vector control) and thus how to enable the generation of robust data and evidence to inform a WHO evidence review process.
WHO meeting on preferred product characteristics for monoclonal antibodies for malaria prevention
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240060405
Category : Medical
Languages : en
Pages : 16
Book Description
Publisher: World Health Organization
ISBN: 9240060405
Category : Medical
Languages : en
Pages : 16
Book Description
WHO working group on late-stage development for malaria vaccines to reduce disease burden
Author:
Publisher: World Health Organization
ISBN: 9240048278
Category : Medical
Languages : en
Pages : 20
Book Description
Publisher: World Health Organization
ISBN: 9240048278
Category : Medical
Languages : en
Pages : 20
Book Description
WHO technical consultation on preferred product characteristics for drugs used in malaria chemoprevention
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240059016
Category : Medical
Languages : en
Pages : 22
Book Description
Publisher: World Health Organization
ISBN: 9240059016
Category : Medical
Languages : en
Pages : 22
Book Description
WHO Recommendations for Prevention and Treatment of Maternal Peripartum Infections
Author: World Health Organization
Publisher: World Health Organization
ISBN: 924154936X
Category : Medical
Languages : en
Pages : 80
Book Description
The goal of the present guideline is to consolidate guidance for effective interventions that are needed to reduce the global burden of maternal infections and its complications around the time of childbirth. This forms part of WHO's efforts towards improving the quality of care for leading causes of maternal death especially those clustered around the time of childbirth in the post-MDG era. Specifically it presents evidence-based recommendations on interventions for preventing and treating genital tract infections during labour childbirth or puerperium with the aim of improving outcomes for both mothers and newborns. The primary audience for this guideline is health professionals who are responsible for developing national and local health protocols and policies as well as managers of maternal and child health programmes and policy-makers in all settings. The guideline will also be useful to those directly providing care to pregnant women including obstetricians midwives nurses and general practitioners. The information in this guideline will be useful for developing job aids and tools for both pre- and inservice training of health workers to enhance their delivery of care to prevent and treat maternal peripartum infections.
Publisher: World Health Organization
ISBN: 924154936X
Category : Medical
Languages : en
Pages : 80
Book Description
The goal of the present guideline is to consolidate guidance for effective interventions that are needed to reduce the global burden of maternal infections and its complications around the time of childbirth. This forms part of WHO's efforts towards improving the quality of care for leading causes of maternal death especially those clustered around the time of childbirth in the post-MDG era. Specifically it presents evidence-based recommendations on interventions for preventing and treating genital tract infections during labour childbirth or puerperium with the aim of improving outcomes for both mothers and newborns. The primary audience for this guideline is health professionals who are responsible for developing national and local health protocols and policies as well as managers of maternal and child health programmes and policy-makers in all settings. The guideline will also be useful to those directly providing care to pregnant women including obstetricians midwives nurses and general practitioners. The information in this guideline will be useful for developing job aids and tools for both pre- and inservice training of health workers to enhance their delivery of care to prevent and treat maternal peripartum infections.
Disease Control Priorities, Third Edition (Volume 6)
Author: King K. Holmes
Publisher: World Bank Publications
ISBN: 1464805253
Category : Medical
Languages : en
Pages : 1027
Book Description
Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.
Publisher: World Bank Publications
ISBN: 1464805253
Category : Medical
Languages : en
Pages : 1027
Book Description
Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.